๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Plasminogen activators, activation inhibitors and alpha2-macroglobulin produced by cultured normal and malignant human cells

โœ Scribed by Olli Saksela; Antti Vaheri; Wolf-Dieter Schleuning; Paolo Mignatti; Sergio Barlati


Book ID
102864948
Publisher
John Wiley and Sons
Year
1984
Tongue
French
Weight
931 KB
Volume
33
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

In the present paper we have characterized the plasminogen activators (PA) synthesized by 25 different human cell lines. Technically easy methods were adopted for concentration and immunological characterization of the activators even in the presence of PA inhibitors. Most cell lines produced uโ€PA (mol. wt 55,000), melanoma and HeLa cells tโ€PA (mol. wt 66,000) and two carcinoma cell lines and normal skin fibroblasts produced no detectable PA. The classical ^125^Iโ€fibrin method was compared to a caseinolytic assay and some of the discrepancies between results obtained with the two methods were shown to be due to cellโ€derived NaDodSO~4~โ€sensitive proteinase inhibitors in culture media. Additionally, synthesis and uptake by the cells of the wideโ€spectrum proteinase inhibitor alphaโ€2โ€macroglobulin (alpha~2~M) were studied by radioimmunoassay and immunofluorescence. No production of alpha~2~M could be measured in any of the malignant cell lines. In normal cells no correlation existed between the production of alpha~2~M and the observed inhibition of PA activity, which indicates that other proteinase inhibitors are produced by the cells.


๐Ÿ“œ SIMILAR VOLUMES


Urokinase-type plasminogen activator and
โœ Olli Saksela; Tapani Hovi; Antti Vaheri ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 872 KB

Human blood rnonocytes in culture differentiate to macrophagelike cells within 1 week. Coinciding with this morphological transition the cells started releasing increasing amounts of the serine proteinase plasminogen activator (PA; Mr 56,000) of the urokinase (u-PA) type and the proteinase inhibitor